What is HC Wainwright's Forecast for enGene FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for enGene to a loss of $1.89 per share from $1.95, while maintaining a Buy rating and a $4.00 price target.
• enGene reported a quarterly loss of $0.47 per share, missing the $0.43 consensus estimate. Analysts overall have a Hold rating on the stock, with an average price target of $11.05.
• Shares opened at $1.77, near the company’s 52-week low of $1.40 and well below its $12.25 high; institutional investors and hedge funds own 64.16% of the stock.

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - HC Wainwright raised their FY2026 earnings per share (EPS) estimates for enGene in a research report issued to clients and investors on Tuesday, September 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.89) for the year, up from their previous estimate of ($1.95). HC Wainwright currently has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for enGene's current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for enGene's Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.76) EPS and FY2029 earnings at ($0.76) EPS.

enGene (NASDAQ:ENGN - Get Free Report) last issued its earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.04).

Several other equities research analysts have also issued reports on the stock. Morgan Stanley lowered shares of enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price objective for the company. in a research note on Thursday, June 18th. Citizens Jmp restated a "market perform" rating on shares of enGene in a report on Wednesday. Citigroup reaffirmed a "market perform" rating on shares of enGene in a research report on Wednesday. Weiss Ratings reiterated a "sell (e+)" rating on shares of enGene in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised enGene from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, enGene presently has an average rating of "Hold" and an average target price of $11.05.

enGene Stock Down 4.3%

Shares of enGene stock opened at $1.77 on Friday. The firm has a market cap of $118.57 million, a price-to-earnings ratio of -1.57 and a beta of -0.28. The stock has a 50-day simple moving average of $1.83 and a 200-day simple moving average of $3.93. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 12.57.

Institutional Trading of enGene

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cresset Asset Management LLC acquired a new position in shares of enGene during the second quarter valued at about $36,000. Raymond James Financial Inc. increased its stake in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after acquiring an additional 7,932 shares during the period. Paloma Partners Management Co bought a new position in enGene during the second quarter valued at about $38,000. Jump Financial LLC acquired a new position in enGene in the 4th quarter valued at approximately $121,000. Finally, Millennium Management LLC raised its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after acquiring an additional 7,472 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.